Approved Drug Label (PDF)
5
Warnings and Precautions
5.1 Anaphylaxis
(Additions and/or
revisions underlined)
In
clinical trials of Palynziq with induction/titration/maintenance dosing, 29
out of 285 (10%) patients experienced a total of 42 anaphylaxis
episodes [see Adverse Reactions (6.1,
6.2)]. The exposure-adjusted rate of anaphylaxis was highest during the
induction and titration phases (0.25 episodes/person-years; 5% of
patients with at least one episode) and decreased in the maintenance phase (0.05
episodes/person-years; 7% of patients with at least one episode). Signs
and symptoms of anaphylaxis reported in clinical trials of Palynziq included
syncope, hypotension, hypoxia, dyspnea, wheezing, chest discomfort/chest
tightness, tachycardia, angioedema (swelling of face, lips, eyes, tongue),
throat tightness, skin flushing, rash, urticaria, pruritus, and
gastrointestinal symptoms (vomiting, nausea, diarrhea). In clinical trials of
Palynziq, anaphylaxis generally occurred within 1 hour after injection (81%;
34/42 episodes); however, delayed episodes also occurred up to 48 hours
after Palynziq administration.
Most
episodes of anaphylaxis occurred within the first year of dosing (69%,
29/42 episodes), but cases also occurred after one year of dosing and up
to 1604 days (4.4 years) into treatment. Management of
anaphylaxis in Palynziq clinical trials included: administration of
auto-injectable epinephrine (48%; 20/42 episodes), corticosteroids
(55%; 23/42 episodes), antihistamines (57%; 24/42 episodes), and/or oxygen (5%;
2/42 episodes). Twenty one out of the 29 (72%) patients who experienced
anaphylaxis were rechallenged with Palynziq and 6 out of the 21 patients who
were rechallenged (29%) had recurrence of anaphylaxis. All anaphylaxis
episodes resolved without sequelae.
Consider
having an adult observer for patients who may need assistance in recognizing
and managing anaphylaxis during Palynziq treatment. If an adult observer is
needed, the observer should be present during and for at least 60 minutes after
Palynziq administration, should be able to administer auto-injectable
epinephrine, and to call for emergency medical support upon its use.
Anaphylaxis
requires immediate treatment with auto-injectable epinephrine. Prescribe
auto-injectable epinephrine to all patients receiving Palynziq and instruct
patients to carry auto-injectable epinephrine with them at all times during
Palynziq treatment. Prior to the first dose, instruct the patient and observer
(if applicable) on how to recognize the signs and symptoms of anaphylaxis, how
to properly administer auto-injectable epinephrine, and to seek immediate
medical care upon its use. Consider the risks associated with auto-injectable
epinephrine use when prescribing Palynziq. Refer to the auto-injectable
epinephrine prescribing information for complete information.
Consider
the risks and benefits of readministering Palynziq following an episode of
anaphylaxis. If the decision is made to readminister Palynziq, administer the
first dose under the supervision of a healthcare provider equipped to manage
anaphylaxis and closely observe the patient for at least 60 minutes following
the dose. Subsequent Palynziq dose titration should be based on patient tolerability
and therapeutic response [see Dosage and
Administration (2.4)].
Consider
premedication with an H1 -receptor antagonist, H2 -receptor antagonist, and/or
antipyretic prior to Palynziq administration based upon individual patient
tolerability [see Dosage and
Administration (2.3)].
Palynziq
is available only through a restricted program under a REMS [see Warnings and Precautions (5.2)].
5.3 Other Hypersensitivity Reactions
(Additions and/or
revisions underlined)
Hypersensitivity
reactions, other than anaphylaxis [see
Warnings and Precautions (5.1), Adverse Reactions (6.1, 6.2)], have been
reported in 204 out of 285 (72%) patients treated with Palynziq.
The exposure adjusted rate of other hypersensitivity reactions was highest
during the induction and titration phases (4.3 episodes/person-year; 50%
of patients with at least one adverse reaction) and decreased in the
maintenance phase (1.3 episodes/person-year; 61% of patients with
at least one adverse reaction).
Consider
premedication with an H1 -receptor antagonist, H2 -receptor antagonist, and/or
antipyretic prior to Palynziq administration based upon individual patient
tolerability [see Dosage and
Administration (2.3)]. Management of hypersensitivity reactions should be
based on the severity of the reaction, recurrence of the reaction, and the
clinical judgement of the healthcare provider, and may include dosage
adjustment, temporary drug interruption, or treatment with antihistamines,
antipyretics, and/or corticosteroids.
6
Adverse Reactions
6.1 Clinical Trial Experience
(Extensive
changes; please refer to label)
6.2 Immunogenicity
(Additions and/or
revisions underlined)
As
with all therapeutic proteins, there is potential for immunogenicity. The
detection of antibody formation is highly dependent on the sensitivity and
specificity of the assay. Additionally, the observed incidence of antibody
(including neutralizing antibody) positivity in an assay may be influenced by
several factors, including assay methodology, sample handling, timing of sample
collection, concomitant medications, and underlying disease. For these
reasons, comparison of the incidence of antibodies to Palynziq in the
studies described below with the incidence of antibodies in other studies or to
other products may be misleading.
All
patients treated with Palynziq developed a sustained total anti-drug antibody
(TAb) response with a majority of patients (91%; N = 235/258) developing that
response by Week 4 of treatment. Mean TAb titers peaked 2 weeks after Palynziq
initiation and remained elevated throughout treatment (greater than 3 years after treatment initiation).
Anti-phenylalanine ammonia lyase (PAL) IgM antibodies were detected in a
majority of patients (98%; N = 265/270) by 2 months after treatment
initiation, with incidence declining over time to 67% at 36 months (N =
114/171). Anti-PAL IgG antibodies were detected in almost all patients (N =
226/227) by 4 months after treatment initiation. Mean anti-PAL IgM and IgG
titers peaked at approximately 3 and 6 months, respectively, after treatment
initiation and remained elevated throughout treatment (greater than 3 years
after treatment initiation). Drug-induced anti-PEG IgM and IgG antibodies were
detected in the majority of patients (98%; N = 277/284 for IgM; and 278/284 for
IgG) with mean titers for both peaking at 1 to 3 months after treatment
initiation [see Drug Interactions (7.1)].
Neutralizing antibodies (NAb) capable of inhibiting PAL enzyme activity were
detected on at least one measurement in the majority of patients (89%; N
= 253/284) over time. Mean NAb titers peaked and reached a plateau at 16
to 20 weeks of treatment and then remained present throughout treatment
(greater than 3 years after treatment initiation).
Twenty-seven
of 29 patients who had anaphylaxis were tested for anti-pegvaliase-pqpz
IgE antibodies, which recognize the PEGylated protein product. Of the 27
patients tested for anti-pegvaliase-pqpz IgE antibodies, 26 patients
tested negative. The one patient who tested positive for anti-pegvaliase-pqpz
IgE antibodies on the screening test did not have sufficient sample to confirm
IgE positivity. This patient tested negative for anti-pegvaliase-pqpz IgE at
routine visits prior to and after the anaphylaxis episode (not at times of
anaphylaxis). Sixty-seven of 285 patients in clinical trials were tested
for both anti-PAL IgE antibodies, which recognize the recombinant PAL protein,
and for anti-pegvaliase-pqpz IgE antibodies during routine study visits (not at
times of anaphylaxis episodes) or during additional visits for hypersensitivity
reactions. Of those 67 patients, 5 (8%) tested positive at least
once for anti-PAL IgE antibodies but negative for anti-pegvaliase-pqpz IgE
antibodies.
The
highest frequency of hypersensitivity reactions (consistent with a Type III
immune complex- mediated hypersensitivity mechanism) occurred within the first
6 months of Palynziq treatment when the mean circulating immune complex (CIC)
concentrations were at their highest and mean complement C3 and C4
concentrations were at their lowest. Mean CIC concentrations decreased and
complement levels increased over time as the exposure-adjusted rate of
hypersensitivity reactions decreased. IgG and IgM CIC concentrations were above
the upper limit of normal in 63% (N = 164/259) and 42% of patients (N = 109/259),
respectively, at 12 weeks of Palynziq treatment and returned towards
baseline with long-term treatment (greater than 3 years after treatment
initiation). 61% of patients (N = 110/180) had complement C3 concentrations
less than lower limit of normal (LLN) at 6 months after treatment initiation
and 38% of patients (N = 94/248) had complement C4 concentrations less than LLN
at 3 months after treatment initiation. The incidence of low complement C3 and
C4 concentrations decreased over time, but approximately 35% (N = 34/96)
and 12% (N = 11/96) of patients had low C3 and C4 concentrations,
respectively, at 36 months after treatment initiation.
Higher
antibody responses for all antibody analytes, including NAb, were associated
with lower mean trough pegvaliase-pqpz concentrations and with higher blood
phenylalanine concentrations.
Hypersensitivity
reactions occurred more frequently in patients with higher antibody titers for
some but not all antibody analytes. Patients with higher mean change in IgG CIC
concentrations from pre-treatment baseline tended to have higher
discontinuation rates than patients with lower mean change in IgG CIC
concentrations. Mean antibody titers for anti-PAL IgG and IgM, TAb, and NAb
remained relatively stable with long-term treatment.
7
Drug Interactions
7.1 Effect of Palynziq on Other PEGylated Products
(Additions and/or
revisions underlined)
In
a single dose study of Palynziq in adult patients with PKU, two patients
receiving concomitant injections of medroxyprogesterone acetate suspension (a
formulation containing PEG 3350) experienced a hypersensitivity reaction.
One of the two patients experienced a hypersensitivity reaction on day 15
after a single Palynziq dosage of 0.67
mg within 15 minutes following medroxyprogesterone acetate injectable suspension,
and subsequently experienced anaphylaxis on day 89 within 30 minutes after the
next dose of medroxyprogesterone acetate injectable suspension. The other
patient experienced a hypersensitivity reaction on day 40 after a single
Palynziq dosage of 0.08 mg within 10 minutes following medroxyprogesterone
acetate injectable suspension. Both patients had high anti-PEG IgG antibody
titers at or around the time of the
hypersensitivity reactions.
In
Palynziq clinical trials, the majority of patients developed anti-PEG IgM and
IgG antibodies after treatment with Palynziq [see Adverse Reactions (6.2)]. The clinical effects of concomitant
treatment with different PEGylated products is unknown. Monitor patients
treated with Palynziq and concomitantly with other PEGylated products for
hypersensitivity reactions including anaphylaxis.
8
Use in Specific Populations
8.1 Pregnancy
(Additions and/or
revisions underlined)
Risk
Summary
Based
on findings in studies of pregnant animals without PKU treated with
pegvaliase-pqpz, Palynziq may cause fetal harm when administered to a pregnant
woman. Limited available data with pegvaliase-pqpz use in pregnant women are
insufficient to inform a drug-associated risk of adverse developmental
outcomes. There are risks to the fetus associated with poorly controlled
phenylalanine concentrations in women with PKU during pregnancy including
increased risk for miscarriage, major birth defects (including microcephaly,
major cardiac malformations), intrauterine fetal growth retardation, and future
intellectual disability with low IQ; therefore, phenylalanine concentrations
should be closely monitored in women with PKU during pregnancy (see Clinical Considerations and Data). Advise
pregnant women of the potential risks to the fetus.
A
reproduction study in pregnant rabbits treated with pegvaliase-pqpz
demonstrated a high incidence of fetal malformations throughout the skeletal
system, and in kidneys, lungs, and eyes. Embryo-fetal toxicity (increased resorptions
and reduced fetal weight) was also observed. These effects occurred at 5 times
the maximum recommended daily dose and were associated with strong signs of
maternal toxicity, including marked reductions in weight gain and food
consumption, and death. A reproduction study in pregnant rats treated with
pegvaliase-pqpz demonstrated an increase in skeletal variations, with no
malformations observed. The effects in rats occurred at 2.8 times the
maximum recommended daily dose. In a pre-/post- natal development
study in rats, pegvaliase-pqpz produced reduced survival of offspring during
lactation, decreases in pup weight and litter size, and delayed sexual
maturation of offspring when administered daily at 13 times the maximum
recommended daily dose. The effects on rat embryo-fetal and post-natal
development were also associated with maternal toxicity.
…
Subcutaneous
administration of 5 mg/kg/day pegvaliase-pqpz (5 times the maximum recommended
daily dose based on bodyweight [mg/kg]) in pregnant rabbits during the period
of organogenesis produced embryo-lethality (increased resorptions), marked
reduction in fetal weight, and fetal malformations. The malformations included
multiple external abnormalities of the head, body and limbs, multiple soft
tissue malformations (reduced size or absence of kidneys, diaphragmatic hernia,
corneal opacity, discoloration or reduced size of eyes, and reduced size of
lungs) and multiple skeletal malformations of the craniofacial bones,
vertebrae, sternebrae, ribs, pelvis, limbs, and digits. An increase in variations
and delayed ossification was also observed in all skeletal regions. The adverse
developmental effects were associated with maternal toxicity, as indicated by
marked impairment of weight gain and food consumption. Deaths associated
with weight loss and abortion occurred in 8% of the pregnant rabbits treated
with 5 mg/kg/day pegvaliase-pqpz.
Subcutaneous
administration of 2 mg/kg/day pegvaliase-pqpz (2 times the maximum
recommended daily dose based on bodyweight [mg/kg]) in pregnant rabbits had no
adverse effects on embryo-fetal development. Systemic exposure to
pegvaliase-pqpz was detected in fetuses from rabbits treated with 2 or 5
mg/kg/day.
Pegvaliase-pqpz
increased fetal alterations when administered daily in pregnant rats at doses
of 8 mg/kg subcutaneously and higher (2.8 times the human steady-state
area under the curve [AUC] at the maximum recommended daily dose) during a
28-day premating period, mating, and through the period of organogenesis. The
fetal alterations were limited to skeletal variations such as cervical ribs,
bifid centra of lumbar and thoracic vertebrae, and incomplete ossification of
squamosal bones, frontal bones, lumbar vertebra arch, and ribs. Daily
administration of 20 mg/kg subcutaneously (13 times the human steady-
state AUC at the recommended maximum daily dose) to pregnant rats produced
reductions in litter sizes and fetal weights, which was associated with
maternal toxicity (decreased body weight, ovarian weight, and food
consumption). The decrease in litter sizes at 20 mg/kg subcutaneously was
secondary to reductions in corpora lutea and implantations. Systemic exposure
to pegvaliase-pqpz was detected in fetuses from rats treated with 20 mg/kg of
pegvaliase-pqpz (13 times the human steady-state AUC at the recommended
maximum daily dose). Subcutaneous administration of 2 mg/kg/day pegvaliase-pqpz
(less than the human steady state AUC at the maximum recommended daily dose) in
pregnant rats had no adverse effects on embryo-fetal development.
Pegvaliase-pqpz
decreased pup weight, litter size, and survival of offspring during lactation,
and delayed sexual maturation of offspring when administered daily in rats at
20 mg/kg subcutaneously (13 times the human steady-state AUC at the
recommended maximum daily dose), with dosing starting before mating and
continuing through lactation. The effects in offspring were associated with
maternal toxicity. No effects in offspring were observed at 8 mg/kg/day
subcutaneously (2.8 times the human steady-state AUC at the recommended
maximum daily dose). This study lacked a complete evaluation of physical and
neurobehavioral development in offspring; however, no effects of
pegvaliase-pqpz were noted in tests of learning and memory.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
MEDICATION GUIDE
(Extensive changes;
please refer to label)